ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1046

Risk of Ocular Comorbidities and Blindness Among Patients with Behçet’s Disease: A Nationwide Population-based Cohort Study in Korea

SE RIM CHOI1, Anna Shin2, Joo Young Shin3, Hokyung Choung3, You-Jung Ha2, Yun Jong Lee4, Eun bong Lee1, Jin Kyun Park1 and Eun Ha Kang2, 1Seoul National University Hospital, Seoul, Republic of Korea, 2Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, 3Department of Ophthalmology, Seoul National University College of Medicine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, 4Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea

Meeting: ACR Convergence 2021

Keywords: Behçet's Syndrome, blindness, Epidemiology, Eye Disorders, population studies

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 8, 2021

Title: Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: To examine the risk of ocular comorbidities in a nation-wide cohort of patients with Behçet’s disease (BD) compared to general population in Korea.

Methods: We conducted a population-based cohort study using 2002-2017 Korean National Health Insurance Service database to examine the risk of diverse ocular comorbidities associated with BD compared to general population. Patients with BD and controls were matched on age and sex at a ratio of 1:5. The primary outcome was blindness. Secondary outcomes were uveitis, and surgical procedure requiring cataract, glaucoma, or retinal diseases. Cox proportional hazard ratio models were used to estimate the hazard ratios (HRs) and 95% confidence interval (CIs) for the outcomes comparing BD patients and controls.

Results: A total of 32,288 BD patients and 161,440 controls were included in the study. During a mean 9.38 years of follow-up, the incidence rate per 100 person-years was 0.12 in the BD group and 0.025 in the control group, respectively. The corresponding HR (95% CI) for the primary outcome was 4.92 (4.27 to 5.69). The risk of all secondary outcomes was significantly elevated among the patients with BD, with the HR (95% CI) of 6.23 (5.97 to 6.51) for uveitis, 1.80 (1.72 to 1.87) for cataract, 5.20 (4.40 to 6.14) for glaucoma, and 2.55 (2.26 to 2.88) for retinal disorders.

Conclusion: This large population-based study showed that BD patients were at higher risk of diverse ocular comorbidities compared to the general population. In particular, the risk of low vision including blindness was the 4.92 times.


Disclosures: S. CHOI, None; A. Shin, None; J. Shin, None; H. Choung, None; Y. Ha, None; Y. Lee, None; E. Lee, None; J. Park, None; E. Kang, None.

To cite this abstract in AMA style:

CHOI S, Shin A, Shin J, Choung H, Ha Y, Lee Y, Lee E, Park J, Kang E. Risk of Ocular Comorbidities and Blindness Among Patients with Behçet’s Disease: A Nationwide Population-based Cohort Study in Korea [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/risk-of-ocular-comorbidities-and-blindness-among-patients-with-behcets-disease-a-nationwide-population-based-cohort-study-in-korea/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-ocular-comorbidities-and-blindness-among-patients-with-behcets-disease-a-nationwide-population-based-cohort-study-in-korea/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology